NCT01748084View on ClinicalTrials.gov

Rituximab in Systemic Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 9, 2013

Primary Completion Date

April 18, 2016

Study Completion Date

April 18, 2016

Conditions
Systemic Sclerosis
Interventions
DRUG

Rituximab

Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone

DRUG

Placebo (NaCl)

Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone

Trial Locations (1)

75014

Cochin Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01748084 - Rituximab in Systemic Sclerosis | Biotech Hunter | Biotech Hunter